Volume 9 • 2022 • Issue 6

Watch the interview with David Coletto, CEO of Abacus Data, on these survey results on CDA Oasis: bit.ly/3UWbHYv Are Canadian still concerned about COVID-19 transmission at the dental office? Canadians feel optimistic that the worst of the pandemic is behind them, and they are more comfortable with visiting the dentist than ever before (81%), consistent with results from the last survey. The concerns about the transmission of COVID-19 by a treatment from a dentist continues to drop, with only 3 in 10 (29%) saying they would be concerned. “We are seeing a confluence of factors that are moving us from a pandemic-crisis world to one where economic issues become more important,” adds Coletto. “This will likely increase public support and demand for federal investment because people are more aware of their economic vulnerability and the risks that these issues are having on their ability to afford dental care.” 13 Issue 6 | 2022 | News and Events A-Oss, a xenogeneic bone graft material, was developed by Osstem Implant in Korea, the world's largest dental implant sales company. A-Oss was launched in 2013, and in 2020, it obtained CE Class III certification, which is the highest level of the European MDD (Medical Device Directive). A-Oss' excellence and product competitiveness demands attention from Canada as well. The pore structure of A-Oss is very similar to that of human bone. The three-dimensional connective pore structure helps fluids, blood vessels, and cells, easily flow in, and acts as a canvas that lays the foundation until new bone is regenerated. Extensive testing conducted by Osstem Implant showed that the high porosity and large surface area of A-Oss resulted in increase blood volume in comparison to other products, which resulted with the formation of excellent new bone. A-Oss can be used for all patients who require bone grafting due to insufficient bone mass. This can be advantageous in areas where sufficient bone mass is required and in areas of aesthetics. A-Oss has volume stability, retention to ensure stable, natural, and esthetic results. Osstem Implant's Bone Science R&D Centre, under the Tissue Regeneration Institute, which developed A-Oss, explained, "Based on Osstem Implant's proprietary deproteinizing technology, immunogens and infectious agents have been removed. A-Oss is a safe and pure deproteinized bone graft material with no immunological rejection. In addition, A-Oss promotes excellent new bone formation by optimizing the surface, pore structure, and granular shape to create a favorable environment for bone cell interaction, proliferation and differentiation.” A-Oss will give clinicians high surgical success rates and price satisfaction. www.hiossen.ca | info@hiossen.ca | �.���.���.���� 20220923_CDA Essentials AD_en_8.125x5.4375 inch_print line_FINAL.pdf 1 10/5/22 1:06 AM